United States securities and exchange commission logo

                           July 7, 2022

       Patrick Amstutz
       Chief Executive Officer
       Molecular Partners Inc.
       245 Main Street
       Cambridge, Massachusetts 02142

                                                        Re: Molecular Partners
Statement on Form F-3
                                                            Filed July 1, 2022
                                                            File No. 333-265960

       Dear Mr. Amstutz:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Dillon
Hagius at 202-551-7967 with any questions.


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Ryan Sansom